TISSUE PLASMINOGEN activator
|
|
- Caren McBride
- 5 years ago
- Views:
Transcription
1 LABORATORY SCIENCES Retinal Toxicity of Commercial Intravitreal Tissue Plasminogen Activator Solution in Cat Eyes Charles J. Hrach, MD; Mark W. Johnson, MD; Adam S. Hassan, MD; Bo Lei, MD; Paul A. Sieving, MD, PhD; Victor M. Elner, MD, PhD Background: We previously reported retinal toxic reactions in rabbit eyes receiving intravitreal injections of commercial tissue plasminogen activator (tpa) in concentrations greater than or equal to 50 µg/0.1 ml, and recent clinical experience suggests that intravitreal tpa solution may produce toxic effects in human eyes. We therefore investigated the dose-dependent retinal toxicity of intravitreal commercial recombinant tpa solution in cat eyes, which have a vascularized inner retina and vitreous volume similar to that of human eyes. Methods: Commercial tpa in L-arginine solution was injected into the mid vitreous cavity of normal cat eyes in doses of 25, 50, 75, and 100 µg/0.1 ml and 200 µg/0.2 ml. Control (fellow) eyes received an equal volume of sterile saline solution. After injection, eyes were evaluated by ophthalmoscopy and electroretinography for 14 days and then enucleated for histopathological evaluation. Results: Fundus pigmentary alterations were observed in eyes receiving doses greater than or equal to 50 µg/0.1 ml. Changes were centered in the area around the injection site, and the area s size increased in proportion to the dosage. Mean electroretinography B-wave amplitude measured at 14 days was significantly reduced in eyes receiving greater than or equal to 50 µg of tpa in a dose-dependent fashion. Light microscopy of the involved areas showed loss of photoreceptor elements with necrosis and proliferation of the retinal pigment epithelium. Conclusion: Intravitreal injection of commercial tpa solution results in dose-dependent retinal toxicity in cat eyes. Clinical Relevance: Because cat eyes are similar to human eyes regarding retinal vascularity and vitreous volume, intravitreal injections of commercial tpa (with L-arginine vehicle) in concentrations greater than 25 µg/0.1 ml are potentially unsafe in human eyes. Arch Ophthalmol. 2000;118: From the Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan School of Medicine, Ann Arbor. None of the authors have any proprietary interest in any product or company described in this article. TISSUE PLASMINOGEN activator (tpa) is a clot-specific thrombolytic enzyme available for clinical use through recombinant DNA technology. Tissue plasminogen activator is used in vitreoretinal surgery to hasten the resolution of postvitrectomy fibrin 1,2 and to facilitate thrombolysis during surgical aspiration of submacular hemorrhage. 3-5 Intravitreal tpa injection has been shown to facilitate subsequent surgical evacuation of subretinal hemorrhage. 6 Recently, Heriot 7 and Hassan et al 8 reported the use of intravitreal tpa and gas to lyse and pneumatically displace submacular hemorrhage. Also, intravitreal tpa is currently under investigation as a possible treatment for acute retinal venous occlusive disease. 9 We previously reported the dosedependent retinal toxicity of commercial tpa solution in rabbit eyes after intravitreal injections in doses greater than or equal to 50 µg/0.1 ml. 10 Specifically, the argininebased vehicle of the commercially available tpa solution was implicated as the toxic component. Some clinicians have subsequently injected higher intravitreal doses in humans, assuming a higher toxic threshold in the human eye owing to its larger vitreous volume and vascularized retina. This study was undertaken to assess the safety of intravitreal tpa in cat eyes, an animal that, in contrast to the rabbit, has a vascularized inner retina and a vitreous volume similar to that of human eyes. RESULTS OPHTHALMOSCOPY AND SLITLAMP BIOMICROSCOPY NoneofthecateyesinjectedwithBSSortPA, 25 µg/0.1 ml, developed anterior chamber or vitreous inflammation. These eyes also maintained a normal fundus appearance throughout the postinjection period. Each eye injected with tpa, 50 µg/ 0.1 ml, showed mild anterior chamber inflammation without visible vitreitis. Two of the eyes appeared normal ophthalmoscopically. In one eye, near the injection site, a localized area of gray tapetal mottling was faintly visible by 3 days after injection and became more apparent by 14 days (Figure 1). 659
2 MATERIALS AND METHODS Commercial recombinant human tpa solution (Activase; Genentech Inc, San Francisco, Calif) was reconstituted as directed to a concentration of 1 mg/ml. The vehicle consisted of L-arginine phosphate (34 mg/ml), phosphoric acid (10 mg/ml) and polysorbate 80 ( 80 mg/l). Small aliquots of tpa were maintained at 70 C until immediately prior to use when they were warmed to room temperature and diluted in sterile balanced salt solution (BSS; Alcon Laboratories, Ft Worth, Tex) to concentrations of 25, 50, 75, and 100 µg/0.1 ml. Institutional guidelines regarding animal experimentation were followed. Domestic short-haired cats weighing 2.5 kg to 4.5 kg were anesthetized with subcutaneous ketamine hydrochloride (4 mg/kg) and xylazine hydrochloride (0.5 mg/kg), and the pupils were dilated with 2.5% phenylephrine hydrochloride and 1% tropicamide. Following baseline indirect ophthalmoscopy and electroretinography (ERG), a 30-gauge needle was inserted into the mid vitreous cavity 4 mm posterior to the limbus in the superotemporal quadrant, taking care to avoid contact with the crystalline lens. In each animal, one eye received intravitreal tpa and the fellow eye received BSS as a control. The injection was performed slowly with the needle directed toward the optic nerve and the bevel oriented anteriorly. The needle was held in place for 30 seconds after injection to minimize reflux from the entry site, and indirect ophthalmoscopy was subsequently performed to look for injection complications. Three animals were tested with each dose. Injection volumes were 0.1 ml of tpa or 0.1 ml of BSS, except for the highest dose at which 0.2 ml of tpa or 0.2 ml of BSS was injected. An anterior chamber paracentesis of 0.1 ml was performed in all eyes receiving injected volumes of 0.2 ml. All eyes were confirmed by pneumotonometry to have an intraocular pressure less than 40 mm Hg 5 minutes after injection. Each eye was dressed with dexamethasonepolymyxin-bacitracin ointment before being returned to the vivarium. All eyes were examined by slitlamp biomicroscopy and indirect ophthalmoscopy at 3, 7, and 14 days after injection, and the ERG was recorded on day 14. Findings from ERG were recorded simultaneously from both eyes of the anesthetized animals using Burian-Alan bipolar corneal electrodes (Hansen Ophthalmic Development Laboratory, Iowa City, Iowa) after corneal anesthesia (0.5% topical proparacaine) and full pupillary dilation (2.5% phenylephrine hydrochloride and 1% tropicamide). The indifferent electrode was a stainless steel needle placed subcutaneously on the back. Signals were amplified at gain at 0.1 Hz to 1000 Hz ( 3 db points), and a 60-Hz notch filter was used to minimize line noise. The responses were digitized at a 1000-Hz rate, averaged to reduce noise and analyzed off line. A Ganzfield 50-millisecond flash was used, with maximum intensity of 2.3 log candela (cd)/m 2. Intensity was controlled with neutral density filters covering a 6-log unit range. Animals were dark-adapted for 1 hour prior to beginning scotopic ERG recordings. B-wave amplitudes were measured from the A-wave trough. Statistical comparisons of ERG data were performed using a t test. B- and A-wave amplitudes of treated eyes were expressed as a percentage of the fellow eye to minimize variation between animals. There were no significant differences in mean A- and B-wave amplitude ratios between dosage groups prior to injection. Euthanasia was performed immediately following the final examination. The eyes were enucleated and refrigerated in phosphate-buffered 2% glutaraldehyde and 4% paraformaldehyde solution after making a slit through the eye wall. Following fixation for 24 to 48 hours, the eyes were hemisected and the temporal hemisphere of each eye was dehydrated, embedded in JB-4 plastic (glycomethacrylate), serial sectioned, and stained with toluidine blue and Lee stain (methylene blue and basic fuchsin) for light microscopy. With higher doses of tpa, toxic reactions became more apparent. In all of the eyes receiving 75, 100, and 200 µg of tpa, mild to moderate anterior chamber inflammation was present. Inflammatory vitreous debris was visible in 1 eye in the 75-µg group and in 2 eyes in both the 100- and 200-µg groups. One eye injected with 200 µg of tpa developed a more severe vitreitis, presumed (without culture) to represent low-grade endophthalmitis. In all other eyes, the mild inflammatory vitreous debris cleared by 14 days after injection. Striking fundus pigmentary alterations were noted in 2 eyes in the 75-µg group (Figure 2) and in all 3 eyes in both the 100- and 200-µg groups (Figure 3 and Figure 4). These fundus changes were typically geographic and centered around the injection site. The fundus alterations typically involved a gray mottling of the tapetal light reflex by 3 days after injection, with the later development of a nonelevated cerebriform pattern of presumed outer retinal folds (best seen in Figure 4), which persisted through the 14-day follow-up period. The involved area was larger with higher tpa doses, and the entire fundus was involved at the 200-µg tpa dose. In eyes receiving the 200-µg tpa dose, widespread vascular attenuation was also apparent by 14 days after injection. ELECTRORETINOGRAPHY Mean B-wave amplitudes (stimulus intensity 0.7 log cd/ m 2 ) were significantly reduced at doses of 50 µg (P=.04) and above in a dose-dependent fashion (Figure 5). A maximum mean (SD) reduction of 86.8% (9.7%) was found in the 200-µg group (P.001). Mean B-wave amplitude ratios were not significantly reduced in the 25-µg group. Mean A-wave amplitudes were also significantly reduced at doses of 75 µg (P.005) and above in a dosedependent fashion (Figure 6). A maximum mean (SD) reduction of 69.5% (6.5%) was found in the 200-µg group (P.001). In the A-wave analysis, this trend was not statistically significant in the 50- or 25-µg groups. Linear regression across all doses showed a tight correlation between amplitude reduction and dose, with R=0.988 for the A-wave regression and R=0.991 for the B-wave regression. LIGHT MICROSCOPY All eyes in the 25-µg group were histologically normal and indistinguishable from control eyes by an examiner masked to treatment group (Figure 7). In the 50-µg group, 2 of 3 eyes were histologically normal. In the remaining eye, 660
3 Figure 1. Fourteen days after intravitreal injection of tissue plasminogen activator, 50 µg/0.1 ml, there is a localized geographic area of gray tapetal mottling near the injection site. Figure 4. Diffuse pigment changes in eye injected with tissue plasminogen activator, 200 µg/0.1 ml, with cerebriform pattern of presumed outer retinal folds. Note the vascular attenuation present 14 days after injection ERG B-Wave Ratio Dose, µg Figure 2. Gray mottling of tapetum 14 days after intravitreal injection of tissue plasminogen activator, 75 µg/0.1 ml, is localized to the area around the injection site. Figure 5. Mean electroretinography (ERG) B-wave amplitude ratios (experimental eye control eye) plotted against tissue plasminogen activator dose ERG A-Wave Ratio Dose, µg Figure 3. Larger area of fundus pigment alteration in eye injected with tissue plasminogen activator, 100 µg/0.1 ml, 14 days after injection. Figure 6. Mean electroretinography (ERG) A-wave amplitude ratios (experimental eye control eye) plotted against tissue plasminogen activator dose. outer retinal damage similar to that seen at higher doses was found in a localized area corresponding to the pigmentary alterations noted ophthalmoscopically (Figure 8). Findings from histopathologic examination revealed retinal cellular damage in all eyes receiving 75, 100, and 200 µg of tpa (Figure 9 and Figure 10). The geographic extent and severity of damage increased with increasing dosage. Photoreceptor outer segments were shortened, and outer retinal folds were seen. Retinal pigment epithelium (RPE) proliferation and necrosis with some pigment clumping was present in affected areas. In correlation with the ophthalmoscopic appearance, the damage was less severe or absent in areas distant from the needle site. There were numerous vitreous polymorphonuclear cells in the eye with presumed low-grade endophthalmitis (200-µg dose), but there was no evidence of retinitis. 661
4 Figure 7. After an intravitreal tissue plasminogen activator injection of 25 µg/0.1 ml, there is preservation of photoreceptor outer segments and normal-appearing retinal pigment epithelium (Lee stain, original magnification 250). Figure 9. After an intravitreal tissue plasminogen activator injection of 100 µg/0.1 ml, there is severe loss of photoreceptor outer segments (curved arrow) coupled with retinal pigment epithelium necrosis and proliferation with pigment clumping (arrow) (Lee stain, original magnification 250). Figure 8. After an intravitreal tissue plasminogen activator injection of 50 µg/0.1 ml, there are shortened photoreceptor outer segments (curved arrow) and a single outer retinal fold (arrow) in a localized area of one eye (Lee stain, original magnification 250). COMMENT This study was engendered by a clinical need to know the retinotoxic threshold for intravitreal commercial tpa solution. Our study demonstrated fundus pigmentary changes in 1 of 3 eyes in the 50-µg group, 2 of 3 eyes in the 75-µg group, and all eyes in both the 100- and 200-µg groups. These changes were most pronounced in the quadrant of injection and involved increasingly larger areas at higher doses. Findings from histopathologic examination showed loss of photoreceptor elements and RPE damage in all eyes with ophthalmoscopic abnormalities, and findings from ERG confirmed functional retinal impairment that roughly corresponded with the results of the histopathologic examination. Significant reductions in mean B-wave amplitudes were first seen with intravitreal injections of 50 µg/ 0.1 ml. As the injected tpa concentration was increased to 75 µg/0.1 ml and higher, both A- and B-wave amplitudes were significantly and progressively reduced compared with control eyes. Since the dark-adapted ERG A- wave reflects rod photoreceptor activity, these results correlate well with the dose-dependent photoreceptor damage found histopathologically beginning with doses of 50 µg/0.1 ml. Figure 10. After an intravitreal tissue plasminogen activator injection of 200 µg/0.2 ml, there are outer retinal folds, severe loss of photoreceptor outer segments, and retinal pigment epithelium proliferation and necrosis with pigment clumping (Lee stain, original magnification 250). A previous study 10 using rabbit eyes found no evidence of retinal toxicity after intravitreal injections of commercial tpa solution in a dose of 25 µg/0.1 ml. One of 4 eyes injected with 50 µg/0.1 ml showed localized loss of photoreceptor cells, and severe retinal damage was seen in eyes receiving commercial tpa doses of 75 µg/0.1 ml or more. Similar to our findings in the current study, the toxic reaction in rabbit eyes was greatest in the quadrant of injection. The previous study demonstrated that the L-arginine vehicle of the commercially available solution, rather than the tpa protein itself, is the toxic agent. The authors speculated that L-arginine may have toxic effects on the outer retina because of its structural similarity to lysine, an amino acid with known retinotoxic potential. Other investigators have also implicated arginine as a retinotoxic agent. After intravitreal injection in rabbit eyes of commercially available aztreonam, which utilizes an L-arginine vehicle, photoreceptor loss and significant reductionsinergamplitudeswerefound. 11 Damagewasmore severe near the injection site and was nearly as severe after injection of an equivalent amount of the L-arginine vehicle alone. Because these 2 previous reports have implicated L-arginine as a toxic component of commercial pharmacologic vehicles, our current study did not repeat assays com- 662
5 paring the retinal toxicity of commercial tpa solution with that of its vehicle alone. Unfortunately, tpa for medical applications is currently unavailable in the United States in preparations that do not contain the L-arginine vehicle. We were surprised to find that the margin of safety for intravitreal commercial tpa solution in cat eyes was similar to that in rabbit eyes. The vitreous volume of cat eyes is larger than that of rabbit eyes and is estimated to be approximately 70% that of human eyes, based on axial length measurements. 12 However, this larger size conferred little protection from the toxic effects of intravitreal tpa. When coupled with the striking geographic distribution of toxic changes around the injection site, this observation suggests that the tpa solution is not diluted uniformly throughout the vitreous cavity. This may be owing to limited dispersion of tpa solution through the formed vitreous gel of adult cat eyes. It is also possible that tpa solution binds to components of the vitreous and creates a drug depot with prolonged local effect. It has been shown that intravitreal tpa concentrations in nonvitrectomized rabbit eyes 30 minutes after injection are approximately twice as high in the injected quadrant compared with more distant sites. 13 Also, the fact that lensectomy/vitrectomy raises the toxic threshold for tpa in rabbit eyes may be explained in part by greater tpa dilution in liquid vitreous compared with formed vitreous gel. 14 Whatever the mechanism, uneven dilution within the vitreous gel has important implications for human eyes, and suggests that tpa should only be injected in concentrations known to be safe, without the assumption of further dilution. Limited data are available regarding the toxic effects of tpa in human eyes. Heriot 7 observed no definite signs of retinal toxicity in 20 human eyes injected with intravitreal commercial tpa in doses of 100 µg/0.1 ml to facilitate pneumatic displacement of submacular hemorrhage. Similarly, Hassan et al 8 found no evidence of retinal or other intraocular toxic reactions to tpa solution in 15 patients receiving intravitreal doses of 25 µg/0.1 ml to 100 µg/ 0.1 ml for the same procedure. Specifically, they observed no retinal pigmentary changes outside areas of previous subretinal hemorrhage, no unexplained visual loss, and no association between tpa dose and visual acuity outcomes. However, Gilbert 15 reported a severe pigmentary retinopathy in a human eye that received an intravitreal tpa injection of 100 µg/0.1 ml. Similarly, Hesse et al 16 recently reported inferior exudative retinal detachment and RPE hyperpigmentation in 4 eyes treated with 100 µg of intravitreal tpa solution, but not in 7 eyes that received 50 µg. Complete preoperative and postoperative ERG recordings in 3 patients revealed a 75% reduction of the scotopic B-wave amplitude postoperatively in a patient treated with 100 µg of tpa and no amplitude reduction in 2 patients treated with 50 µg. Finally, LaPuente et al 17 observed mild fundus pigmentary changes after intravitreal tpa injection in concentrations as low as 33 µg/0.1 ml. Factors affecting the sensitivity of a given human eye to toxic reactions by commercial tpa solution are unknown, but may include vitreous volume, extent of vitreous liquefaction, and position of the needle tip relative to the retina. Although increased fundus pigmentation may partially protect the rabbit retina from the toxic effects of gentamicin, it is not known whether this may also be a factor in human eyes injected with tpa. 18 In summary, we have demonstrated that intravitreal injection of commercially available tpa solution results in dose-dependent retinal toxicity in cat eyes. This toxic effect preferentially involves the outer retina and RPE. Toxic effects are greatest in the injected quadrant, implying that tpa does not diffuse uniformly throughout the vitreous. Based on these findings, we recommend avoiding intravitreal injections into human eyes of commercially available tpa (with L-arginine vehicle) in concentrations greater than 25 µg/0.1 ml. Accepted for publication July 20, This study was partially supported by grant NEI ROI EY 6094 from the National Institutes of Health, Bethesda, Md. Presented in part at the Association for Research in Vision and Ophthalmology Annual Meeting, Ft Lauderdale, Fla, May 11, 1998, and at the Retina Society Annual Meeting, Washington, DC, September 26, The authors would like to thank Csaba Martonyi, COPRA, for his invaluable help with fundus photography. Corresponding author: Mark W. Johnson, MD, Kellogg Eye Center, 1000 Wall St, Ann Arbor, MI ( markwj@umich.edu). REFERENCES 1. Jaffe GJ, Abrams GW, Williams GA, Han DP. Tissue plasminogen activator for postvitrectomy fibrin formation. Ophthalmology. 1990;97: Williams DF, Bennett SR, Abrams GW, et al. Low-dose intraocular tissue plasminogen activator for treatment of postvitrectomy fibrin formation [letter]. Am J Ophthalmol. 1990;109: Johnson MW, Olsen K, Hernandez E. Tissue plasminogen activator thrombolysis during surgical evacuation of experimental subretinal hemorrhage. Ophthalmology. 1992;99: Lewis H. Intraoperative fibrinolysis of submacular hemorrhage with tissue plasminogen activator and surgical drainage. Am J Ophthalmol. 1994;118: Kamei M, Tano Y, Maeno T, et al. Surgical removal of submacular hemorrhage using tissue plasminogen activator and perfluorocarbon liquid. Am J Ophthalmol. 1996;121: Kimura AE, Reddy CV, Folk JC, et al. Removal of subretinal hemorrhage facilitated by preoperative intravitreal tissue plasminogen activator [letter]. Retina. 1994;14: Heriot WJ. Further experience in management of submacular hemorrhage with intravitreal tpa. Paper presented at: American Academy of Ophthalmology Vitreoretinal Update; October 24, 1997; San Francisco, Calif. 8. Hassan AS, Johnson MW, Schneiderman TE, et al. Management of submacular hemorrhage with intravitreal tpa injection and pneumatic displacement. Ophthalmology. 1999;106: Lahey JM, Fong DS, Kearney J. Intravitreal tissue plasminogen activator for acute central retinal vein occlusion. Ophthalmic Surg Lasers. 1999;30: Johnson MW, Olsen KR, Hernandez E, et al. Retinal toxicity of recombinant tissue plasminogen activator in the rabbit. Arch Ophthalmol. 1990;108: Loewenstein A, Zemel E, Lazar M, et al. Drug-induced retinal toxicity in albino rabbits: the effects of imipenem and aztreonam. Invest Ophthalmol Vis Sci. 1993; 34: Polyak S. The cat. In: The Vertebrate Visual System. Chicago, Ill: University of Chicago Press; 1957: Egana BC, LaPuente CR, Peyman GA. Intravitreal distribution of tissue plasminogen activator in nonvitrectomized and fibrin-filled vitrectomized eyes [abstract]. Invest Ophthalmol Vis Sci. 1997;38(suppl): Irvine WD, Johnson MW, Hernandez E, et al. Retinal toxicity of human tissue plasminogenactivatorinvitrectomizedrabbiteyes.archophthalmol.1991;109: Gilbert H. Pigmentary retinopathy following intravitreal injection of tissue plasminogen activator. Paper presented at: Vitreous Society Annual Meeting; September 20, 1997; New Orleans, La. 16. Hesse L, Schmidt J, Kroll P. Management of acute submacular hemorrhage using recombinant tissue plasminogen activator and gas. Graefes Arch Clin Exp Ophthalmol. 1999;237: LaPuenteCR,PeymanGA,EganaBC,etal.GuidelinesforintravitrealtreatmentofvascularocclusionswithrtPA[abstract]. InvestOphthalmolVisSci.1998;39(suppl): Zemel E, Loewenstein A, Lei B, et al. Ocular pigmentation protects the rabbit retina from gentamicin-induced toxicity. Invest Ophthalmol Vis Sci. 1995;36:
Can intravitreal tissue plasminogen activator and SF6 gas facilitate management of macular degeneration with photodynamic therapy?
European Journal of Ophthalmology / Vol. 18 no. 4, 2008 / pp. 591-594 Can intravitreal tissue plasminogen activator and SF6 gas facilitate management of macular degeneration with photodynamic therapy?
More informationEvidence that a-wave Latency of the Electroretinogram Is Determined Solely by Photoreceptors
Evidence that a-wave Latency of the Electroretinogram Is Determined Solely by Photoreceptors Hui Qiu*, Eriko Fujiwara, Mu Liu, Byron L. Lam and D. I. Hamasaki *Department of Ophthalmology, Hamamatsu University
More informationSubmacular hemorrhage in age-related macular degeneration vitreous injections of recombinant tissue plasminogen activator (rtpa) and gas [16]. The pro
S.C. Tsai, J.M. Lin, and H.Y. Chen INTRAVITREOUS RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR AND GAS TO TREAT SUBMACULAR HEMORRHAGE IN AGE-RELATED MACULAR DEGENERATION San-Chang Tsai, Jane-Ming Lin, and Hsin-Yi
More informationManagement of Acute Submacular Hemorrhage with Intravitreal Injection of Tenecteplase, Anti-vascular Endothelial Growth Factor and Gas
pissn: 1011-8942 eissn: 2092-9382 Korean J Ophthalmol 2016;30(3):192-197 http://dx.doi.org/10.3341/kjo.2016.30.3.192 Original Article Management of Acute Submacular Hemorrhage with Intravitreal Injection
More informationTitle: NLRP3 plays a protective role during the development of age related macular degeneration through the induction of IL-18 by drusen components.
Title: NLRP3 plays a protective role during the development of age related macular degeneration through the induction of IL-18 by drusen components. Sarah L. Doyle 1*, Matthew Campbell 2*, Ema Ozaki 2,
More informationTESTING INTRAVITREAL TOXICITY OF BEVACIZUMAB (AVASTIN)
TESTING INTRAVITREAL TOXICITY OF BEVACIZUMAB (AVASTIN) ROBERTA P. A. MANZANO, MD, GHOLAM A. PEYMAN, MD, PALWASHA KHAN, MD, MUHAMET KIVILCIM, MD Purpose: To evaluate the retinal toxicity of varying doses
More informationLong-term Effect of Plasmin on the Vitreolysis in Rabbit Eyes
Korean J Ophthalmol Vol. 18:35-40, 2004 Long-term Effect of Plasmin on the Vitreolysis in Rabbit Eyes Nam Ju Kim, MD*, Hyeong Gon Yu, MD*, * *, Young Suk Yu, MD*, * *, Hum Chung, MD*, * * *Department of
More informationINTRODUCTION METHODS. Trans Am Ophthalmol Soc 2005;103:98-107
VITRECTOMY FOR THE TREATMENT OF SUBMACULAR HEMORRHAGES FROM MACULAR DEGENERATION: A COMPARISON OF SUBMACULAR HEMORRHAGE/MEMBRANE REMOVAL AND SUBMACULAR TISSUE PLASMINOGEN ACTIVATOR ASSISTED PNEUMATIC DISPLACEMENT
More informationF/G 6/18 MECHANISMS OCT 75 T LAWHILL, F SHARP, N SPEED DAMD17-74-C-4026 IHEF. NL UNCLASSIFIlED
F/G 6/18 MECHANISMS 7 A-AI03 183 LOUISVILLE UNIV OF RETINAL KY SCHOOL DAMAGE OF FROM MEDICINE CHRONIC LASER RAOIATION.(U) OCT 75 T LAWHILL, F SHARP, N SPEED DAMD17-74-C-4026 IHEF NL UNCLASSIFIlED )J yreport
More informationHIGH DOSE TISSUE PLASMINOGEN ACTIVATOR (TPA) (100 MCG/0.1 ML) AND C3F8 GAS IN PNEUMATIC DISPLACEMENT OF SUBMACULAR
HIGH DOSE TISSUE PLASMINOGEN ACTIVATOR (TPA) (100 MCG/0.1 ML) AND C3F8 GAS IN PNEUMATIC DISPLACEMENT OF SUBMACULAR HAEMORRHAGE. Stephen A.M. De Souza MD, FRCSC Matthew J Welch MD, Raza M Shah MD, Alan
More informationIntroduction to Full Field ERGs
Introduction to Full Field ERGs ISCEV Full Field ERG Standard (Recording protocols and their physiological basis) Laura J. Frishman, PhD University of Houston October 17, 2016 Cellular origins and mechanisms
More informationPRECISION PROGRAM. Injection Technique Quick-Reference Guide. Companion booklet for the Video Guide to Injection Technique
Injection Technique Quick-Reference Guide PRECISION PROGRAM Companion booklet for the Video Guide to Injection Technique Available at www.ozurdexprecisionprogram.com Provides step-by-step directions with
More informationPerspectives on Screening for Diabetic Retinopathy. Dr. Dan Samaha, Optometrist, MSc Clinical Lecturer School of Optometry, Université de Montréal
Perspectives on Screening for Diabetic Retinopathy 1 Dr. Dan Samaha, Optometrist, MSc Clinical Lecturer School of Optometry, Université de Montréal Current standards 2 According to the Canadian Diabetes
More informationOcular Complications after Intravitreal Bevacizumab Injection in Eyes with Choroidal and Retinal Neovascularization
Original Article Ocular Complications after Intravitreal Bevacizumab Injection in Eyes with Choroidal and Retinal Neovascularization Aimal Khan, P.S Mahar, Azfar Nafees Hanfi, Umair Qidwai Pak J Ophthalmol
More informationSubmacular hemorrhage can occur due to a variety. Pneumatic Displacement of a Dense Submacular Hemorrhage with or without Tissue Plasminogen Activator
Original Article 852 Pneumatic Displacement of a Dense Submacular Hemorrhage with or without Tissue Plasminogen Activator Po-Min Yang, MD; His-Kung Kuo, MD; Min-Lun Kao, MD; Yung-Jen Chen, MD; Hsih-Hao
More informationOCT and muti-focal ERG findings in spontaneous closure of bilateral traumatic macular holes
Doc Ophthalmol (2008) 116:159 164 DOI 10.1007/s10633-008-9113-1 CASE REPORT OCT and muti-focal ERG findings in spontaneous closure of bilateral traumatic macular holes Hongling Chen Æ Mingzhi Zhang Æ Shizhou
More informationAssessment of macular function by multifocal electroretinogram before and after macular hole surgery
420 Department of Ophthalmology, Gunma University School of Medicine, Japan Y-J Si S Kishi K Aoyagi Correspondence to: Ying-Jie Si, MD, Department of Ophthalmology, Gunma University School of Medicine,
More informationFunduscopic Interpretation Understanding the Fundus: is that normal?
Funduscopic Interpretation Understanding the Fundus: is that normal? Gillian McLellan BVMS PhD DVOphthal DECVO DACVO MRCVS With thanks to Christine Heinrich and all who contributed images Fundus Retina
More informationStudy of clinical significance of optical coherence tomography in diagnosis & management of diabetic macular edema
Original Research Article Study of clinical significance of optical coherence tomography in diagnosis & management of diabetic macular edema Neha Kantilal Desai 1,*, Somesh Vedprakash Aggarwal 2, Sonali
More informationCoagulative necrosis in a malignant melanoma of the choroid at the macula with extensive subretinal hemorrhage
Coagulative necrosis in a malignant melanoma of the choroid at the macula with extensive subretinal hemorrhage Robert D. Yee, Robert Y. Foos, and Bradley R. Straatsma The authors present a case report
More informationFACING YOUR FUNDIC FEARS: EXAMINATION OF THE OCULAR FUNDUS J. Seth Eaton, VMD, DACVO Cornell University Veterinary Specialists
FACING YOUR FUNDIC FEARS: EXAMINATION OF THE OCULAR FUNDUS J. Seth Eaton, VMD, DACVO Cornell University Veterinary Specialists The goal of a thorough fundus examination is to clinically evaluate the structures
More informationOCCLUSIVE VASCULAR DISORDERS OF THE RETINA
OCCLUSIVE VASCULAR DISORDERS OF THE RETINA Learning outcomes By the end of this lecture the students would be able to Classify occlusive vascular disorders (OVD) of the retina. Correlate the clinical features
More informationCorticosteroids have been a standard treatment for various
The Safety of Intraocular Ketorolac in Rabbits Eyal Margalit, 1 Lance J. Kugler, 1 Matthew V. Brumm, 2 Jane L. Meza, 3 Uday B. Kompella, 1,4 Edith R. Escobar, 1,4 and Gerald R. Christensen 1 From the Departments
More informationSudden Vision Loss. Brendan Girschek, MD, FRCSC, FACS Vitreoretinal Surgery Cedar Valley Medical Specialists
Sudden Vision Loss Brendan Girschek, MD, FRCSC, FACS Vitreoretinal Surgery Cedar Valley Medical Specialists My Credentials -Residency in Ophthalmology at the LSU Eye Center in New Orleans, LA -Fellowship
More informationOutline. Brief history and principles of ophthalmic ultrasound. Types of ocular ultrasound. Examination techniques. Types of Ultrasound
Ultrasound and Intraocular Tumors 2015 Ophthalmic Photographers' Society Mid-Year Program Cagri G. Besirli MD, PhD Kellogg Eye Center University of Michigan Outline Brief history and principles of ophthalmic
More informationDestruction of the Indoleomine-Accumuloting Amocrine Cells Alters the ERG of Rabbits
Destruction of the Indoleomine-Accumuloting Amocrine Cells Alters the ERG of Rabbits Kazuo Nakarsuka* and D. I. Hamasaki The indoleamine-accumulating amacrine cells in the rabbit's retina were destroyed
More informationEye Examination Techniques in Horses
Eye Examination Techniques in Horses Dennis E. Brooks DVM, PhD Dip ACVO University of Florida brooksd@mail.vetmed.ufl.edu Basic Instruments How to tell the potential of vision? PLRs (retina, CN 2, chiasm,
More informationInternational Journal of Basic and Applied Physiology
Multifocal Electroretinography in Assessment Of Diseases Of Posterior Pole Of Retina JagdeepKaur S. Dani*, Mitesh M. Sinha**, Archana H. Patel**, Anju B. Mehta ***, Geeta B. Nair**** *Associate Professor,
More informationUse of Scanning Laser Ophthalmoscope Microperimetry in Clinically Significant Macular Edema in Type 2 Diabetes Mellitus
Use of Scanning Laser Ophthalmoscope Microperimetry in Clinically Significant Macular Edema in Type 2 Diabetes Mellitus Fumihiko Mori, Satoshi Ishiko, Norihiko Kitaya, Taiichi Hikichi, Eiichi Sato, Akira
More informationPreoperative Electroretinogram and Postoperative Visual Outcome in Patients with Diabetic Vitreous Hemorrhage
Preoperative Electroretinogram and Postoperative Visual Outcome in Patients with Diabetic Vitreous Hemorrhage Takashi Hiraiwa*, Naoichi Horio*, Hiroko Terasaki*, Toshimitsu Suzuki*, Etsuko Yamamoto*, Masayuki
More informationVenturi versus peristaltic pumps 33 vitrectomy dynamics 34 Fluorescein, vitreous staining 120
Subject Index Accurus 35, 83 Aflibercept, diabetic macular edema management 167, 168 Air-forced infusion, Stellaris PC 12, 13 Alcon Constellation, see Constellation system Autoclave sterilization lens
More informationRare Presentation of Ocular Toxoplasmosis
Case Report Rare Presentation of Ocular Toxoplasmosis Rakhshandeh Alipanahi MD From Department of Ophthalmology, Nikookari Eye Hospital, Tabriz University of Medical Sciences, Tabriz, Iran. Correspondence:
More informationVITREOUS FLOATERS AND PHOTOPSIA AS PREDICTORS OF VITREORETINAL PATHOLOGY
Basrah Journal Of Surgery VITREOUS FLOATERS AND PHOTOPSIA AS PREDICTORS OF VITREORETINAL PATHOLOGY Salah Zuhair Al-Asadi MB,ChB, FRCS, FIBMS, Lecturer of Ophthalmology, College of Medicine, University
More informationReliability and Significance of Measurements of a-wave Latency in Rats
Reliability and Significance of Measurements of a-wave Latency in Rats Eriko Fujiwara*, Hui Qiu, Mu Liu, Byron L. Lam, J.-M. Parel, G. Inana and D. I. Hamasaki *Department of Ophthalmology, Fukuoka University
More informationCase Series and Brief Reports. Ocul Oncol Pathol 2017;3:34 40 DOI: /
Case Series and Brief Reports Received: April 14, 2016 Accepted after revision: July 24, 2016 Published online: September 14, 2016 Acute Hemorrhagic Retinopathy following Intravitreal Melphalan Injection
More informationThe Effect of Pupil Dilation on Scanning Laser Polarimetry With Variable Corneal Compensation
C L I N I C A L S C I E N C E The Effect of Pupil Dilation on Scanning Laser Polarimetry With Variable Corneal Compensation Amjad Horani, MD; Shahar Frenkel, MD, PhD; Eytan Z. Blumenthal, MD BACKGROUND
More informationINTRAVITREAL INJECTION OF TISSUE PLASMINOGEN ACTIVATOR FOR CENTRAL RETINAL VEIN OCCLUSION*
19 Elman Final TS 11/9/01 11:24 AM Page 219 INTRAVITREAL INJECTION OF TISSUE PLASMINOGEN ACTIVATOR FOR CENTRAL RETINAL VEIN OCCLUSION* BY Michael J. Elman, MD, Robert Z. Raden, MD (BY INVITATION), AND
More informationLongitudinal Validation Study: Streptozotocin-Induced Diabetes as a Model of Diabetic Retinopathy in Brown Norway Rats
Longitudinal Validation Study: Streptozotocin-Induced Diabetes as a Model of Diabetic Retinopathy in Brown Norway Rats Robin Dean, Robert Sukhu, Leslie Nemeth, Qin Zhang, Isaac Hakim, Ali Ebramhimnejad,
More information(Received 8 March 1965)
J. Physiol. (1965), 180, pp. 837-845 837 With 1 plate and 4 text-figures Printed in Great Britain THE EFFECT OF OCCLUDING THE RETINAL AND CHOROIDAL CIRCULATIONS ON THE ELECTRO- RETINOGRAM OF MONKEYS BY
More informationMelanin Associated Antigen Induced Uveitis in Rats
Melanin Associated Antigen Induced Uveitis in Rats Comparative Biosciences, Inc. 786 Lucerne Drive Sunnyvale, CA 94085 Telephone: 408.738.9260 www.compbio.com Premier Preclinical Contract Research Organization
More informationPREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland
AD Award Number: W81XWH-07-1-0 TITLE: PRINCIPAL INVESTIGATOR: CONTRACTING ORGANIZATION: University of REPORT DATE: TYPE OF REPORT: PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick,
More informationOPHTHALMOLOGY AND ULTRASOUND
Vet Times The website for the veterinary profession https://www.vettimes.co.uk OPHTHALMOLOGY AND ULTRASOUND Author : JAMES OLIVER Categories : Vets Date : April 28, 2008 JAMES OLIVER discusses why ultrasound
More informationEPIRETINAL MEMBRANE & VITREOMACULAR TRACTION
EPIRETINAL MEMBRANE & VITREOMACULAR TRACTION Management of ERM and VMT K.V.Chalam,MD,PhD,MBA,FACS Professor and Director of Retina Loma Linda Eye Institute Los Angeles, USA REVIEW ANATOMY The vitreous
More informationRecurrences of retinal detachment after vitreoretinal surgery, and surgical approach
European Journal of Ophthalmology / Vol. 11 n. 2, 2001 / pp. 166-170 Recurrences of retinal detachment after vitreoretinal surgery, and surgical approach Z. KAPRAN 1, O.M. UYAR 1, V. KAYA 2, K. ELTUTAR
More informationAcute Retinal Necrosis Secondary to Varicella Zoster Virus in an Immunosuppressed Post-Kidney Transplant Patient
CM&R Rapid Release. Published online ahead of print September 20, 2012 as Aperture Acute Retinal Necrosis Secondary to Varicella Zoster Virus in an Immunosuppressed Post-Kidney Transplant Patient Elizabeth
More informationBasic Electrophysiology, the Electroretinogram (ERG) and the Electrooculogram (EOG) - Signal origins, recording methods and clinical applications
Basic Electrophysiology, the Electroretinogram (ERG) and the Electrooculogram (EOG) - Signal origins, recording methods and clinical applications The body is a complex machine consisting of the central
More informationADVANCED DIAGNOSTIC TECHNIQUES
DIVISION OF VISION SCIENCES SESSION: 2008/2009 DIET: 1ST ADVANCED DIAGNOSTIC TECHNIQUES VISP216 LEVEL:2 MODULE LEADER: DR GUNTER LOFFLER B.Sc/B.Sc. (HONS) OPTOMETRY MAY 2009 DURATION: 2 HOURS CANDIDATES
More informationEffects of Intravitreal Ropivacaine on Retinal Thickness and Integrity in the Guinea Pig
VOLUME 66, NUMBER 4, JUL /AuousT 2005 Effects of Intravitreal Ropivacaine on Retinal Thickness and Integrity in the Guinea Pig Gonul Olmez, MD1; Sevin Soker Cakmak, MD2; Sevda Ipek Soker, MD3; Yusuf Nergiz,
More informationA retrospective nonrandomized study was conducted at 3
Department of Ophthalmology, Kangbuk Samsung Hospital, Sungkyunkwan University College of Medicine 1, Seoul, Korea Hangil Eye Hospital 2, Incheon, Korea Seoul National University Bundang Hospital 3, Seongnam,
More informationChoroidal detachment following retinal detachment surgery: An analysis and a new hypothesis to minimize its occurrence in high-risk cases
European Journal of Ophthalmology / Vol. 14 no. 4, 2004 / pp. 325-329 Choroidal detachment following retinal detachment surgery: An analysis and a new hypothesis to minimize its occurrence in high-risk
More informationLocal Intra-arterial Fibrinolysis in Treatment of Incomplete Ophthalmic Artery Occlusion A Case Report
CASE REPORT Local Intra-arterial Fibrinolysis in Treatment of Incomplete Ophthalmic Artery Occlusion A Case Report Shih-Ting Fang, Pao-Sheng Yen 1, Chien-Chung Chen, Yuan-Chieh Lee Department of Ophthalmology,
More informationDisease-Specific Fluorescein Angiography
Ruth E. Picchiottino, CRA Disease-Specific Fluorescein Angiography 15 Disease-Specific Fluorescein Angiography Recommendations for tailoring retinal fluorescein angiography to diabetic retinopathy, macular
More informationChoroidal Neovascularization in Sympathetic Ophthalmia
Choroidal Neovascularization in Sympathetic Ophthalmia Lucia Sobrin, Miguel Cordero Coma, C. Stephen Foster Case Report A 49-year-old man presented after a ruptured globe repair of his left eye status
More informationA Case of Childhood Vitrectomy Performed for Dense Vitreous Hemorrhage Secondary to Leukemia Therapy and Tumor Lysis Syndrome
Published online: January 27, 2015 1663 2699/15/0061 0034$39.50/0 This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC)
More informationScleral buckling. Surgical Treatment
Dr. Ayman M. Khattab MD, FRCS professor of Ophthalmology Cairo University Surgical Treatment Pneumatic retinopexy. Primary pars plana vitrectomy. 1 Indications for scleral buckling. SB is used to treat
More informationGLAUCOMA SUMMARY BENCHMARKS FOR PREFERRED PRACTICE PATTERN GUIDELINES
SUMMARY BENCHMARKS FOR PREFERRED PRACTICE PATTERN GUIDELINES Introduction These are summary benchmarks for the Academy s Preferred Practice Pattern (PPP) guidelines. The Preferred Practice Pattern series
More informationWhen Retina is not detached anymore. Alexandra Mouallem, Agnès Glacet-Bernard Service du Professeur Souied Le 19/03/2014
When Retina is not detached anymore, Agnès Glacet-Bernard Service du Professeur Souied Le 19/03/2014 Medical History Mr V. 57 yo man December 2013 : Bullous superior retinal detachment caused by 2 retinal
More informationConjunctival displacement to the corneal side for oblique-parallel insertion in 25-gauge vitrectomy
European Journal of Ophthalmology / Vol. 18 no. 5, 2008 / pp. 848-851 SHORT COMMUNICATIONS & CASE REPORTS Conjunctival displacement to the corneal side for oblique-parallel insertion in 25-gauge vitrectomy
More informationVeterinary Procedures and Treatment Guidelines for the DioVet Laser System
Veterinary Procedures and Treatment Guidelines for the DioVet Laser System GLAUCOMA Transscleral Diode Laser Protocol for Glaucoma There are two transscleral diode laser protocols used for glaucoma treatment
More informationElectro Retinogram Basics and Major Clinical Applications
Ophthalmic Instrumentation Electro Retinogram Basics and Major Clinical Applications Meena C K. DNB, Thomas Cherian MS, Elizabeth Chacko BSc Optometry Electroretinogram is the electrical potential generated
More informationAustralian and New Zealand College of Veterinary Scientists. Fellowship Examination. Veterinary Ophthalmology Paper 1
Australian and New Zealand College of Veterinary Scientists Fellowship Examination June 2014 Veterinary Ophthalmology Paper 1 Perusal time: Twenty (20) minutes Time allowed: Three (3) hours after perusal
More informationEpiretinal Membrane Formation in Terson Syndrome
ESEVIER Epiretinal Membrane Formation in Terson Syndrome Masahiko Yokoi, Manabu Kase, Toshiki Hyodo, Midori Horimoto, Fumihiko Kitagawa and Renpei Nagata Department of Ophthalmology, Teine Keijinkai Hospital,
More informationOptometric Postoperative Cataract Surgery Management
Financial Disclosures Optometric Postoperative Cataract Surgery Management David Dinh, OD Oak Cliff Eye Clinic Dallas Eye Consultants March 10, 2015 Comanagement Joint cooperation between two or more specialists
More informationCauses of failure of pneumatic retinopexy
VOL. 9 NO. PHILIPPINE JOURNAL OF Ophthalmology JULY ORIGINAL ARTICLE - SEPTEMBER 00 Roberto E. Flaminiano, MD Robert T. Sy, MD Milagros H. Arroyo, MD Pearl Tamesis-Villalon, MD Department of Ophthalmology
More informationchorioretinal atrophy
British Journal of Ophthalmology, 1987, 71, 757-761 Retinal microangiopathy in pigmented paravenous chorioretinal atrophy SURESH R LIMAYE AND MUNEERA A MAHMOOD From the Ophthalmology Service, DC General
More informationLearn Connect Succeed. JCAHPO Regional Meetings 2017
Learn Connect Succeed JCAHPO Regional Meetings 2017 Intravitreal Injection Technique Updated Recommendations from an Expert Panel Sophie J. Bakri, M.D. Professor of Ophthalmology Vitreoretinal Diseases
More informationCASE PRESENTATION. DR.Sravani 1 st yr PG Dept of Ophthalmology
CASE PRESENTATION DR.Sravani 1 st yr PG Dept of Ophthalmology Name : X X X X X Age : 50yrs Sex : male Occupation : Farmer Residence : Mothkur CHIEF COMPLAINTS : - Diminision of vision in Right Eye since
More informationUC SF. g h. Eye Trauma. Martha Neighbor, MD Emergency Services San Francisco General Hospital University of California
UC SF Eye Trauma sf g h Martha Neighbor, MD Emergency Services San Francisco General Hospital University of California Goals Recognize vision threatening eye emergencies Treat them when we can Know when
More informationCLINICAL SCIENCES. Repeatability and Reproducibility of Fast Macular Thickness Mapping With Stratus Optical Coherence Tomography
CLINICAL SCIENCES Repeatability and Reproducibility of Fast Macular Thickness Mapping With Stratus Optical Coherence Tomography Antonio Polito, MD; Michele Del Borrello, MD; Miriam Isola, MHS; Nicola Zemella,
More informationNEW YORK UNIVERSITY SCHOOL OF MEDICINE DEPARTMENT OF OPHTHALMOLOGY EDUCATIONAL OBJECTIVES AND GOALS
NEW YORK UNIVERSITY SCHOOL OF MEDICINE DEPARTMENT OF OPHTHALMOLOGY EDUCATIONAL OBJECTIVES AND GOALS Revision Date: 6/30/06 Distribution Date: 7/6/06 The Department of Ophthalmology at the NYU Medical Center
More information2/26/2017. Sameh Galal. M.D, FRCS Glasgow. Lecturer of Ophthalmology Research Institute of Ophthalmology
Sameh Galal M.D, FRCS Glasgow Lecturer of Ophthalmology Research Institute of Ophthalmology No financial interest in the subject presented 1 Managing cataracts in children remains a challenge. Treatment
More informationEFFECTIVENESS OF RADIAL OPTIC NEUROTOMY FOR ISCHEMIC CENTRAL RETINAL VEIN OCCLUSION ABSTRACT
ORIGINAL ARTICLE EFFECTIVENESS OF RADIAL OPTIC NEUROTOMY FOR ISCHEMIC CENTRAL RETINAL VEIN OCCLUSION Mir Ali Shah 1, Faisal Nawaz 2, Adnan Alam 3, Bilal Khan 4 1-4 Department of Ophthalmology, Lady Reading
More informationICO-Ophthalmology Surgical Competence Assessment Rubric Vitrectomy (ICO-OSCAR:VIT)
ICO-Ophthalmology Surgical Competence Assessment Rubric Vitrectomy (ICO-OSCAR:VIT) Date Resident Evaluator Novice (score = 2) Beginner (score = 3) Advanced Beginner (score = 4) Competent (score = 5) Not
More informationCystoid macular edema associated with limbal melanoma*
Graefe's Arch Clin Exp Ophthalmol (1983) 221:101-105 Graefe's Archive for CliniCal and Experimental Ophthalmology Springer-Verlag 1983 Cystoid macular edema associated with limbal melanoma* J. Reimer Wolter
More informationComparative electroretinograms in argon laser
British Journal of Ophthalmology, 1983, 67, 520-525 Comparative electroretinograms in argon laser and xenon arc panretinal photocoagulation JAMES C. LIANG,' GERALD A. FISHMAN,' FELIPE U. HUAMONTE,' AND
More informationRecovery of Retinal Pigment Epithelial Function After Ischemia in the Rabbit
Investigative Ophthalmology & Visual Science, Vol. 32, No. 1, January 1991 Copyright Association for Research in Vision and Ophthalmology Recovery of Retinal Pigment Epithelial Function After Ischemia
More informationYasser R. Serag, MD Tamer Wasfi, MD El- Saied El-Dessoukey, MD Magdi S. Moussa, MD Anselm Kampik, MD
Microperimetric Evaluation of Brilliant Blue G- assisted Internal Limiting Membrane Peeling By Yasser R. Serag, MD Tamer Wasfi, MD El- Saied El-Dessoukey, MD Magdi S. Moussa, MD Anselm Kampik, MD The internal
More informationA,kCetazolamide lowers intraocular pressure
Ocular and systemic effects of acetazolamide in nephrectomized rabbits Zvi Friedman,* Theodore Krupin, and Bernard Becker The effects of acetazolamide on intraocular pressure (IOP) were studied on rabbits
More informationMultifocal Electroretinograms in Patients with Branch Retinal Artery Occlusion
Multifocal Electroretinograms in Patients with Branch Retinal Artery Occlusion Akira Ohshima, Shigeru Hasegawa, Ritsuko Takada, Mineo Takagi and Haruki Abe Department of Ophthalmology, Niigata University
More informationT.opically applied corticoids were shown to produce in man an increase in intraocular pressure, a reduction in outflow facility,
Aqueous outflow facility in monkeys and the effect of topical corticoids Mansour F. Armaly The ocular effects of topically applied dexamethasone 21-phosphate and subconjunctivally administered methylprednisolone
More informationOcular and Periocular Trauma. Tina Rutar, MD. Assistant Professor of Ophthalmology and Pediatrics. Director, Visual Center for the Child
Ocular and Periocular Trauma Tina Rutar, MD Assistant Professor of Ophthalmology and Pediatrics Director, Visual Center for the Child University of California, San Francisco Phone: 415-353-2560 Fax: 415-353-2468
More informationThe Cellular Basis of Electroretinogram (ERG) Signals
The Cellular Basis of Electroretinogram (ERG) Signals Laura J. Frishman, PhD University of Houston October 19, 2015 Cellular origins and mechanisms of generation of the various waves of the ERG Sherry,
More informationCONTRAINDICATIONS None. (4)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use JETREA safely and effectively. See full prescribing information for JETREA JETREA (ocriplasmin) injection,
More informationFinancial Disclosures
Financial Disclosures Consultant Genentech, Regeneron, Allergan, Thrombogenics, Optos, and ArcticDx Grant Support Regeneron, Allergan Mathew W. MacCumber, MD, PhD Professor & Assoc. Chair for Research
More informationInterface Vitrectomy Offers an Alternative for Surgery
Published in the January/February 2012 issue of Retinal Physician Magazine. Interface Vitrectomy Offers an Alternative for Surgery By leaving surface tension management agents in the eye, many vitreoretinal
More informationGraefe's Archive. Ophthalmology Springer-Verlag Artificial anterior chamber for the growing of membranes on lens implants*
Graefe's Arch Clin Exp Ophthalmol (1983) 221:55-60 Graefe's Archive for Clinical and Experimental Ophthalmology Springer-Verlag 1983 Artificial anterior chamber for the growing of membranes on lens implants*
More informationSurgical Anatomy Ear and Eye. Presenters: Dr. Jim Hurrell and Dr. Dennis McCurnin
Surgical Anatomy Ear and Eye Presenters: Dr. Jim Hurrell and Dr. Dennis McCurnin A Warm Welcome from My Faculty TEAM and Me!!! 2 The Pledge of Allegiance 3 The Senses 4 Hearing 3 Layers of Ear EXTERNAL
More informationRETINAL CONDITIONS RETINAL CONDITIONS
GENERAL INFORMATION RETINAL CONDITIONS RETINAL CONDITIONS WHAT ARE RETINAL CONDITIONS? Retinal conditions affect the light-sensitive tissue at the back of eye known as the retina. They include diseases
More informationClosed System and Expanded Instrumentation Improves MIVS Outcomes
CLOSED SYSTEM AND GRIESHABER EXPANDED DSP INSTRUMENTATION Instrumentation for IMPROVES SurgeryMIVS OUTCOMES Closed System and Expanded Instrumentation Improves MIVS Outcomes By Martin Charles, MD I have
More informationScleral Buckling Using a Non-contact Wide-Angle Viewing System with a 25-Gauge Chandelier Endoilluminator
pissn: 1011-8942 eissn: 2092-9382 Korean J Ophthalmol 2017;31(6):533-537 https://doi.org/10.3341/kjo.2017.0044 Original Article Scleral Buckling Using a Non-contact Wide-Angle Viewing System with a 25-Gauge
More informationA Guide to Administering
A Guide to Administering INDICATIONS AND USAGE YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment
More informationReferences 1. Melberg NS, Thomas MA AJO 120: , Welch JC AJO 124: 698, Hirata A, Yonemura N, et al. AJO 130:611, 2000.
Central or Paracentral Scotoma Associated with Nasal Placement of Chandelier Infusion During Vitrectomy with Fluid-Air Exchange J. Michael Jumper MD, Sara J. Haug MD PhD, Arthur D. Fu MD, Robert N. Johnson
More informationCase Report: Indocyanine Green Dye Leakage from Retinal Artery in Branch Retinal Vein Occlusion
Case Report: Indocyanine Green Dye Leakage from Retinal Artery in Branch Retinal Vein Occlusion Hiroki Fujita, Kyoko Ohno-Matsui, Soh Futagami and Takashi Tokoro Department of Visual Science, Tokyo Medical
More informationYear 2 MBChB Clinical Skills Session Ophthalmoscopy. Reviewed & ratified by: Mr M Batterbury Consultant Ophthalmologist
Year 2 MBChB Clinical Skills Session Ophthalmoscopy Reviewed & ratified by: o Mr M Batterbury Consultant Ophthalmologist Learning objectives o To understand the anatomy and physiology of the external and
More informationE, Ixperimental allergic encephalomyelitis
Experimental allergic optic neuritis in guinea pigs: preliminary report Narsing A. Rao, Mark O. M. Tso," and Lorenz E. Zimmerman An experimental model for acute allergic optic neuritis was produced in
More informationOCULAR DISORDERS REPORT BOSTON TERRIER
OCULAR DISORDERS REPORT BOSTON TERRIER 1991-1999 2000-2009 2010-2012 TOTAL DOGS EXAMINED 2723 6803 2004 Diagnostic Name # % # % # % GLOBE 0.110 microphthalmia 1 0.0% 1 0.0% 0 EYELIDS 20.140 ectopic cilia
More informationThe Effects of Myristyl 7-Picolinium Chloride on the Rabbit Retina: Morphologic Observations
The Effects of Myristyl 7-Picolinium Chloride on the Rabbit Retina: Morphologic Observations Esther Zernel,* Anat Loewenstein,\ Moshe Lazar,f and Ido Perlman* Purpose. This study was designed to localize
More informationMisdiagnosed Vogt-Koyanagi-Harada (VKH) disease and atypical central serous chorioretinopathy (CSC)
HPTER 12 Misdiagnosed Vogt-Koyanagi-Harada (VKH) disease and atypical central serous chorioretinopathy (S) linical Features VKH disease is a bilateral granulomatous panuveitis often associated with exudative
More informationAround The Globe in 60 Minutes
Around The Globe in 60 Minutes Around the GLOBE in Sixty Minutes Basic Ocular Anatomy, Examination, and Diagnostic Techniques Introduction Focusing on canine and feline ocular anatomy and basic examination
More informationCOMPARISON OF INTRAVITREAL TRIAMCINOLONE INJECTION VS LASER PHOTOCOAGULATION IN ANGIOGRAPHIC MACULAR EDEMA IN DIABETIC RETINOPATHY
Original Article COMPARISON OF INTRAVITREAL TRIAMCINOLONE INJECTION VS LASER PHOTOCOAGULATION IN ANGIOGRAPHIC MACULAR EDEMA IN DIABETIC RETINOPATHY Aggarwal Somesh V 1, Shah Sonali N 2, Bharwada Rekha
More information